By Sid Ruttala

Large cap investing produces very few moments where the reported number and the share price move in opposite directions with such conviction. On 18 August, CSL Limited (ASX: CSL) reported a statutory net loss after tax of US$2.6 billion, the worst headline result in the company’s listed history. The shares closed the day up roughly 17 per cent.

For anyone who learned that profits drive share prices, this looks like the market losing its mind. It is closer to the opposite. The market spent FY26 pricing CSL for continued deterioration, and this result was the first credible evidence in two years that the core business has stopped going backwards. The loss was accounting. The guidance was cash.

That distinction is the whole article.

How CSL got here

CSL is three businesses. CSL Behring collects human plasma and turns it into therapies, principally immunoglobulin, along with haemophilia products and albumin. CSL Seqirus makes seasonal influenza vaccines. CSL Vifor, acquired in 2022, sells iron deficiency and dialysis related products.

For most of the past two decades, Behring was one of the highest quality franchises on the ASX. Plasma collection is capital intensive, heavily regulated and genuinely difficult to replicate at scale, which is precisely why investors were willing to pay a premium multiple for a very long time.

That premium unwound with unusual violence. CSL fell roughly 52 per cent across FY26, making it one of the worst performers in the S&P/ASX 200. The reset began in August 2025 with a workforce reduction of up to 15 per cent and a planned demerger of the influenza vaccine business. A second downgrade arrived in October when weak vaccination rates forced another rethink. Two resets in as many quarters did more damage to management’s forecasting credibility than to the underlying franchise. Most of the remaining damage was done on 11 May, when an interim chief executive review cut FY26 guidance again.

By early June the shares had found a floor. They then rallied 49.5 per cent from the 3 June low into the result, which is worth holding in mind. A large part of the recovery had already happened before 18 August.

What the result actually said

Revenue was US$15.8 billion, down 1 per cent at constant currency. Underlying NPATA was US$3.1 billion, down 2 per cent. Underlying NPAT was US$2.8 billion, down 3 per cent. Gross profit fell 2 per cent to US$8.5 billion and the operating result fell 3 per cent to US$6.8 billion. Cash flow from operations was US$3.5 billion.

None of that is growth. All of it landed at or slightly ahead of a market that had been repeatedly disappointed.

The statutory loss came from two places. CSL booked US$7.1 billion of pre-tax impairments across FY26, of which US$5.5 billion landed in the second half, and incurred US$799 million of restructuring costs. The impairments reflect adverse changes to commercial outlooks, the arrival of generic competition, regulatory developments and revised site utilisation assumptions.

By division, Behring revenue fell 1 per cent to US$11.4 billion. Immunoglobulin revenue was broadly flat at about US$6.25 billion, held back by Medicare Part D and channel inventory normalisation, but second half revenue grew 7 per cent year on year and RBC pointed to second half immunoglobulin growth of 14 per cent on its measure. Haemophilia fell 1 per cent to US$1.5 billion, with HEMGENIX revenue up 25 per cent. Albumin dropped 17 per cent to US$1.1 billion on Chinese government cost containment. Vifor rose 3 per cent to US$2.4 billion. Seqirus fell 8 per cent to US$2.0 billion, though seasonal influenza revenue itself rose 4 per cent to US$1.6 billion, with the decline explained by non-recurring avian flu revenue in the prior year.

Why the market bought it

Three things.

First, the FY27 guidance beat. CSL expects group revenue broadly in line with FY26 at constant currency, but underlying NPAT growth of approximately 5 per cent excluding restructuring and impairment items, against consensus of 2 per cent. That implies NPAT of roughly US$2.98 billion versus consensus of US$2.83 billion. Behring is guided to mid single digit revenue growth, Seqirus to low single digit growth, and Vifor down approximately 25 per cent on iron generics.

Second, the second half immunoglobulin performance. Behring is the reason to own CSL. If immunoglobulin demand is reaccelerating and plasma collection economics are improving, the rest is detail. RBC described the result as a beat across revenue, EBITDA and NPATA, with every segment exceeding revenue and gross profit expectations.

Third, the capital return. CSL announced a new US$1.1 billion buyback and declared a final dividend of US$1.62 per share, taking the full year to US$2.92. A company that genuinely believed it was impaired does not simultaneously commit to buying back its own stock.

Interim chief executive Gordon Naylor described FY26 as a year of reset with a clear path back to sustainable growth. Management is entitled to say that. Investors are entitled to check it in twelve months.

What a US$7.1 billion impairment does and does not tell you

This is the part worth explaining plainly, because it recurs across the market every reporting season.

An impairment is an accounting adjustment to the carrying value of an asset on the balance sheet. It is non-cash. It does not touch the operating cash flow the business generated this year, and it does not change the cash the business will generate next year. What it does tell you is that the price previously paid for something, or the future assumed for it, is no longer supportable.

So the impairment is backward looking and the guidance is forward looking, and the market was buying the second.

But it would be dishonest to treat the write-down as meaningless. US$7.1 billion of impairment is a formal admission that capital was destroyed. A meaningful part of that traces to Vifor, an acquisition that has not delivered and is now guided to decline 25 per cent in FY27. Shareholders paid real money for those assets. Writing them down clears the runway for the reported numbers to look better from here, which is convenient, and it is exactly why underlying and statutory results should both be read rather than one being discarded.

The risks that did not go away on 18 August

CSL still has no permanent chief executive. The global search has been running since February. A business attempting a multi year transformation with an interim leader carries an obvious strategic risk, and the eventual appointment could bring another change in emphasis.

The Seqirus demerger, originally planned for completion by the end of FY26, was deferred in October 2025 and still has no confirmed completion date. That is unresolved value, and unresolved value can move in either direction.

Vifor is guided to fall approximately 25 per cent in FY27 as iron generics arrive. That is a known headwind, but known headwinds have a habit of being deeper than modelled.

Seqirus faces softer United States immunisation rates, which management expects to decline more slowly than in recent seasons rather than to recover.

The transformation program targets US$500 million to US$550 million in annual savings by FY28, against roughly US$176 million delivered in FY26. Cost savings are real, but a business the market once valued on growth cannot be repriced upward on cost savings alone.

Sentiment is not unanimous. Macquarie entered reporting season with CSL as its least preferred healthcare name and indicated the result did not change that view.

Finally, the guidance is stated at FY26 exchange rates, and the dividend is declared in United States dollars and is largely unfranked. For Australian income investors, particularly SMSF retirees accustomed to fully franked yield, that matters more than the headline payout suggests.

Valuation, honestly

Before the result, the average analyst price target sat at about A$137.84, with the most bullish at A$196.48 and UBS carrying a buy rating and a A$158 target. The stock traded around A$157 to A$159 on the day of the result. Those targets are pre-result and will be revised upward by some brokers and left alone by others, so treating them as a valuation anchor right now would be a mistake.

The more useful question is what multiple a business growing underlying profit at roughly 5 per cent deserves. CSL spent a decade priced as a compounder. It is currently guiding to something closer to a recovering industrial with a very good core franchise attached. Those two descriptions carry very different multiples, and the gap between them is where the argument sits.

What long term investors should take from this

The lesson generalises well beyond CSL.

First, separate accounting events from cash events. A statutory loss driven by impairment tells you about the past. Guidance, cash flow and capital returns tell you about the next twelve months. Both matter, but they answer different questions.

Second, be careful with quality narratives that have already been repriced. CSL was not a bad business in FY26. It was an expensive business meeting a period of genuine operational difficulty, and the de-rating was more about the starting multiple than the ending one.

Third, note how much of the move happened before the news. The stock rose 49.5 per cent from its June low before it reported. By the time a turnaround is obvious in the numbers, a good deal of it is usually in the price.

TAMIM Takeaway

CSL reported a US$2.6 billion statutory loss and the shares rose 17 per cent, because the market was pricing further deterioration and instead received an FY27 guidance beat, evidence of a second half recovery in immunoglobulin and a US$1.1 billion buyback. The US$7.1 billion of impairments is non-cash and backward looking, but it is also a formal acknowledgement that capital was destroyed, most visibly in Vifor.

What the market may be missing is that the recovery case now depends on execution rather than valuation. The easy repricing has happened. From here, CSL has to actually deliver mid single digit Behring growth, appoint a permanent chief executive, resolve the Seqirus demerger and absorb a 25 per cent decline in Vifor.

For long term investors, the practical question is not whether the worst is behind CSL. It is whether a business guiding to roughly 5 per cent underlying profit growth should be valued the way a compounder was valued, or the way a recovering industrial is valued. That question is not answered by one result, and it will not be answered by one year.

The mindset to bring is patience with the business and scepticism toward the narrative. Turnarounds are usually slower and less linear than the first good day suggests.

__________________________________________________________________________________

Disclaimer: CSL Limited (ASX: CSL) is held in TAMIM portfolios as at the date of article publication. Holdings can change substantially at any time.